See associations below
|I BCL2||BCL2, follicular lymphoma, apoptosis inhibiting protein|
|I BER EP4||Epithelial antigen, BER-EP4|
|I CD117||CD117, c-kit, myeloid and mast cell|
|I CK HMW||Cytokeratin high molecular weight; 34BE12|
|I CK5/6||Cytokeratin 5/6 usual ductal hyperplasia|
|I CK7||Cytokeratin 7, 54kD|
|I CK8/18||Cytokeratin 8/18 aytpical ductal hyperplasia|
|I CK20||Cytokeratin 20|
|I ECAD||E-cadherin epithelial cell, ductal-type breast|
|I ER||Estrogen receptor|
|I GCDFP15||Gross cystic disease fluid protein 1|
|I HER2||HER2/neu (IVD)|
|I KI67||Ki67 cell proliferation marker|
|I P53||p53 tumor suppressor gene protein, prognostic|
|I P63||p63 nucelar, tumor supressor gene protein|
|I PLAP||Placental alkaline phosphatase, germ cell tumors, adenocarcinoma|
|I PR||Progesterone receptor|
|I SMA||Smooth muscle actin|
|* Performed at affiliate laboratory|
|I CATHD*||Cathepsin D|
|I CK 8*||Cytokeratin 8|
|I CK19*||Cytokeratin 19|
Technical component (TC) available for all markers
Paraffin embedded tissue block
3 slides (3-5 uM) per marker on adhesion glass
If submitting HER2 protein over-expression by immunohistochemistry,
HER2(ERBB2) gene amplification by in situ hybridization or estrogen /
progesterone receptor expression by immunohistochemistry, the specimen must
follow fixation guidelines listed below:
1. Specimens should be immersed in fixative within one hour of the biopsy or
2. If delivery of a resection specimen to the pathology department is delayed (eg,
specimens from remote sites), the tumor should be bisected prior to the
immersion in fixative. In such cases, it is important that the surgeon ensure
that the identity of the resection margins is retained in the bisected specimen;
alternatively, the margins may be separately submitted.
3. The time of removal of the tissue and the time of immersion of the tissue in
fixative should be recorded and submitted to the laboratory.
Ship ambient. Protect from extreme temperature with an ice pack. Separate ice pack from specimen.
Inadequate fixation; Improper labeling
Marker and tissue specific
Results are reviewed by a board-certified pathologist to determine if tissues are positive or negative for the marker. These results may be used to assist in determining appropriate patient therapy or treatment. Immunohistochemistry combines the principles of histochemistry with the high degree of molecular specificity of the antibody-antigen reaction. The use of an enhanced-polymer detection system provides many benefits including increased sensitivity, fewer procedural steps as compared to conventional techniques, and a reduction in non-specific background staining.
MPLN offers a range of markers by Immunohistochemistry including hematologic, tissue specific, infectious agents and proliferation antigens.
1. Press M et al. (2002). Steroids. 67:799-813.
2. Perttschuk et al. (1996). Cancer. 77:2514-15.
3. Battifora et al. (1993). Appl Immunohistochem. 1:39-45.